This article is more than 5 years old. Information may no longer be current.
Patients with psoriasis experience cardiometabolic comorbidities
Click Here to Manage Email Alerts
Patients with psoriasis have a prevalence of certain comorbidities that contribute to metabolic syndrome, according to recently published study results in the Journal of the American Academy of Dermatology.
Researchers used the Truven Health Analytics MarketScan database, which includes claims for commercially insured U.S. patients, to measure the extent of comorbidities in patients with psoriasis. The database included 1.22 million patients with at least one claim with a psoriasis diagnosis between 2008 and 2014.
The psoriasis population included 469,097 patients aged at least 18 years (mean age, 49.6 years; 48% male) who had at least two health claims in any diagnosis field for psoriasis using the ICD-9-CM code 696.1 with a first psoriasis diagnosis between July 1, 2008 and June 30, 2014, representing 6.5% of an estimated 7.2 million adults with psoriasis in 2010.
There were 292,999 patients (mean age, 50.4 years; 47.2% male) who met continuous enrollment criteria, representing 4.1% of U.S. adults with psoriasis in 2010.
Hyperlipidemia (prevalence, 45.64%; incidence, 30.83%), hypertension (42.19% and 24.19%), depression (17.91% and 12.68%), type 2 diabetes (17.45% and 8.44%) and obesity (14.38% and 11.5%) were the most common comorbidities in the psoriasis population when prevalence and incidence of 24 comorbidities were assessed.
The psoriasis population and continuously enrolled population had similar prevalence and incidence rates of selected comorbidities, except for type 2 diabetes, hyperlipidemia, hypertension and depression.
“Comorbidities are common among real-world patients with psoriasis,” the researchers wrote. “The prevalence of metabolic syndrome increased in the Unties States form 32.9% in 2003-2004 to 34.7% in 2011-2012. In this analysis of adult patients with psoriasis, the most prevalent comorbidities in the continuously enrolled population were hyperlipidemia (48.6%), hypertension (44.7%), depression (18.7%), type 2 diabetes mellitus (18.3%) and obesity (15%). These comorbidities, except for depression, contribute to metabolic syndrome, a disorder that leads to an increased rate of heart disease and stroke.” – by Bruce Thiel
Disclosure: Shah reports being employed at Celgene Corp. at the time of study conduct and having access to stocks, stock options and restricted stock units in Celgene Corp. Please see the full study for a listing of the other researchers’ relevant financial disclosures.
Click Here to Manage Email Alerts